CLINICAL_TRIALS
trial_result
· 2024-10-15
Clinical Trial Update: SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma [Phase 2]
Summary
A Phase 2 trial examining SBRT followed by surufatinib with immunotherapy for biliary tract carcinoma is currently suspended.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Zhejiang Cancer Hospital | Conditions: Biliary Tract Carcinoma | Phase 2 | Status: SUSPENDED